The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
Project Number5P01AA029541-02
Contact PI/Project LeaderSAMET, JEFFREY H.
Awardee OrganizationBOSTON MEDICAL CENTER
Description
Abstract Text
ABSTRACT
One quarter of the global population is infected with the bacillus Mycobacterium tuberculosis and is at risk of
developing active tuberculosis (TB) disease and death, especially persons living with HIV (PLWH). Alcohol use
is increasingly being recognized as a driver of the TB epidemic, and may be a vital means to mitigate HIV/TB
morbidity and mortality. TB preventive therapy (TPT) is an important approach in preventing the progression of
latent TB infection to active TB disease. However, TPT does not prevent new or repeat TB infection, thus
PLWH who drink alcohol may remain at increased risk for TB acquisition, even after receipt of TPT. Heavy
alcohol use is common among persons living with HIV (PLWH). While the increased risk for active TB is
attributed to alcohol-related immunosuppression leading to latent TB re-activation, the role of alcohol use in
acquiring new or repeat TB infection and progression to active TB disease after TPT has not been extensively
examined, including among PLWH. Those who complete TB treatment have extensive post-TB morbidity and
almost a 4-fold higher risk of mortality. The role of both heavy alcohol use and HIV in promoting lung disease
after TB treatment is not clear. The central goal of the International Uganda Russia Boston Alcohol Network
for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Center is to examine the role of alcohol use
on new TB acquisition, occurrence of active TB disease after TPT, and post-TB lung disease among PLWH.
This new knowledge will enable future development of interventions that can reduce alcohol’s impact on TB-
related morbidity and mortality among PLWH. The Center will be comprised of 4 components (Administrative
Core, Biostatistics and Data Management [BDM] Core, Uganda Project, Russia Project) that will work
synergistically to accomplish the following primary objectives: 1) Examine the role of alcohol use in driving
the acquisition of new TB infection and the occurrence of active TB disease after TPT in PLWH in Uganda
(Uganda Project). This new knowledge will inform potential new interventions to reduce risk of TB acquisition
and active disease; 2) Determine the relationship between alcohol use and lung disease after treatment for
active TB disease among PLWH and qualitatively evaluate factors to tailor alcohol and smoking interventions
in the setting of TB treatment in PLWH (Russia Project); 3) Conduct high quality data management and
statistical analyses for HIV/alcohol research (BDM Core); 4) Foster multidisciplinary international collaborations
to promote innovative and rigorous HIV/alcohol research (Administrative Core); and 5) Provide ongoing training
and mentoring to develop junior and mid-career investigators into future leaders in HIV/alcohol research
(Administrative Core). The structure of the International URBAN ARCH Center will ensure effective
administrative and scientific integration of a broad range of activities designed to synergistically grow the field
of HIV/alcohol/TB prevention and treatment.
Public Health Relevance Statement
NARRATIVE
The International Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS
(URBAN ARCH) Center will generate new generalizable knowledge about the complex relationship between
TB, HIV, and alcohol use in order to accelerate the future development of interventions that can reduce
alcohol’s impact on TB-related morbidity and mortality among PLWH.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS/HIV problemAccountingAddressAftercareAlcohol consumptionAlcoholsAutomobile DrivingBacillusBiometryBostonCause of DeathCessation of lifeClinicalCollaborationsComplexDataData Management ResourcesDiseaseEnsureEpidemicFosteringFutureGoalsHIVHIV/TBHeavy DrinkingImmunosuppressionImpairmentIndividualInfectious AgentInternationalInterventionKnowledgeLungLung diseasesMalignant neoplasm of lungMeasuresMentorsMorbidity - disease rateMycobacterium tuberculosisNIH Office of AIDS ResearchOutcomePersonsPopulationPredispositionPreventionPreventive therapyPulmonary TuberculosisRecording of previous eventsResearchResearch PersonnelResearch Project GrantsRifampinRiskRoleRussiaStatistical Data InterpretationStructureTestingTrainingTuberculosisUgandaWorkactive methodacute coronary syndromealcohol interventionalcohol researchcareerco-infectioncohortcomorbiditydata managementdesignexperiencehigh riskimprovedinnovationisoniazidlung healthmortalitymortality riskmultidisciplinarypreventrifapentinesmoking interventiontherapy developmenttuberculosis treatment
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
005492160
UEI
JZ8RQC4EMDZ5
Project Start Date
10-September-2021
Project End Date
31-August-2026
Budget Start Date
01-September-2022
Budget End Date
31-August-2023
Project Funding Information for 2022
Total Funding
$1,325,994
Direct Costs
$1,118,223
Indirect Costs
$207,771
Year
Funding IC
FY Total Cost by IC
2022
National Institute on Alcohol Abuse and Alcoholism
$1,325,994
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AA029541-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AA029541-02
Patents
No Patents information available for 5P01AA029541-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AA029541-02
Clinical Studies
No Clinical Studies information available for 5P01AA029541-02
News and More
Related News Releases
No news release information available for 5P01AA029541-02
History
No Historical information available for 5P01AA029541-02
Similar Projects
No Similar Projects information available for 5P01AA029541-02